An overview of the diagnosis and management of MDS, including recent treatment, was discussed in a paper published in the American Journal of Hematology.
Researchers sought to determine whether elevated platelet-to-lymphocyte ratio and plasma C-reactive protein level would help predict prognosis for patients with MDS.
A head-to-head comparison of 7-day and 5-day treatment schedule of azacitidine in patients with higher risk myelodysplastic syndromes revealed trends in overall survival and time to transformation to leukemia.
Researchers sought to identify features related to failure to reach allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndromes.
Researchers sought to determine whether nonablative chemotherapy followed by HLA-mismatched allogeneic T-cell infusion would be safe and effective in older patients with AML or MDS.
As myeloproliferative neoplasms (MPN) are a particularly rare form of blood cancer without a clear cause, it may be difficult to understand how lifestyle factors can affect both MPN risk and symptom burden. What has research suggested about the ways certain lifestyle factors affect MPNs?
Researchers sought to determine whether detecting MRD with mutational analysis and FCM may aid in predicting disease progression following myeloablative allo-HSCT in patients with MDS.
As myeloproliferative neoplasms (MPNs) are a rare form of blood cancer, patients may not be aware of its effects. How do MPNs affect a patient’s quality of life, and what do your patients need to know?
Researchers seek to identify biomarkers that may be predictive of erythroid response in patients with lower-risk myelodysplastic syndromes without a chromosome 5q deletion.
Researchers sought to review the EU’s marketing authorization for luspatercept to treat select patients with MDS or transfusion-dependent beta thalassemia.
Researchers sought to determine whether pevonedistat plus azacitidine would result in a lower residual mutation load than seen with azacitidine alone in patients with MDS.
Researchers sought to determine whether there is a link between exposure to a soluble CD40 ligand (sCD40L) and expression of TNFα in bone marrow mononuclear cells from patients with MDS.
Researchers sought to determine whether paroxysmal nocturnal hemoglobinuria clones might predict treatment responses for patients with MDS and aplastic anemia.
A team of researchers sought to determine whether morphologic dysplasia may serve as a biomarker of risk for transition to myelodysplastic syndrome in patients with clonal cytopenia of undetermined significance.
A team of investigators sought to evaluate outcomes following combination treatment with eprenetapopt and azacitadine in TP53-mutant myelodysplastic syndromes, as well as in oligoblastic acute myeloid leukemia.
A phase 3 trial suggests higher responses when epoetin alfa is added to lenalidomide in treatment of erythropoietin-refractory myelodysplastic syndromes.
Researchers reviewed the challenges and future developments in ICI combination therapies for the treatment of patients with acute myeloid leukemia and myelodysplastic syndromes.
Among some patients with myelodysplastic syndrome, gene expression signatures appear to be predictive of response and primary resistance to azacitidine.
With the exception of alloSCT and iron chelation therapy, many guideline treatments may not improve survival among patients with myelodysplastic syndrome.
Researchers studied survival in reduced-intensity conditioning HSCT vs non-HSCT approaches for older, transplantation-eligible patients with advanced MDS.
The first-in-class imetelstat demonstrated clinically meaningful red blood cell transfusion independence rates in lower-risk MDS, according to results of a phase 2 trial.